Gilead Sciences Inc. Revenue 2007–2025
Gilead Sciences Inc. annual/quarterly revenue history and growth rate from 2007 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Gilead Sciences Inc. revenue for the quarter ending March 31, 2026 was 7.0 B, a 4.39% increase year-over-year.
- Gilead Sciences Inc. revenue for the twelve months ending March 31, 2026 was 28.5 B, a 0.86% increase year-over-year.
- Gilead Sciences Inc. annual revenue for 2025 was 29.4 B, a 2.40% increase from 2024.
- Gilead Sciences Inc. annual revenue for 2024 was 28.8 B, a 6.04% increase from 2023.
- Gilead Sciences Inc. annual revenue for 2023 was 27.1 B, a 0.60% decrease from 2022.
- Gilead Sciences Inc. annual revenue for 2022 was 27.3 B.
Gilead Sciences Inc. (GILD) — Frequently Asked Questions
Gilead Sciences Inc. (GILD) is a publicly traded US company in the Healthcare sector. It has a market capitalization of $158.20B. In fiscal 2025 it reported revenue of $29.44B and net income of $8.51B. Explore GILD's stock price, financial statements, earnings history, margins and key ratios below.
What is Gilead Sciences Inc.'s market cap?
Gilead Sciences Inc. (GILD) has a market capitalization of $158.20B.
What is the GILD stock price?
GILD trades at $126.06 (+3.77% on the day).
How much revenue does Gilead Sciences Inc. make?
Gilead Sciences Inc. reported revenue of $29.44B in fiscal 2025.
Is GILD profitable?
In fiscal 2025, Gilead Sciences Inc. reported net income of $8.51B.
What is GILD's P/E ratio?
Based on diluted EPS, GILD has a price-to-earnings (P/E) ratio of about 18.6.